| Dermal Cell News 2.38 October 31, 2016 | |
|
|
|
|
TOP STORYUNR/CSDE1 Drives a Post-transcriptional Program to Promote Melanoma Invasion and Metastasis The authors show that the RNA binding protein UNR/CSDE1 is overexpressed in melanoma tumors and promotes invasion and metastasis. [Cancer Cell] Abstract | Graphical Abstract |
|
|
|
|
PUBLICATIONS(Ranked by impact factor of the journal)DERMAL STEM CELLS & TISSUE REGENERATIONmTORC1 and mTORC2 Regulate Skin Morphogenesis and Epidermal Barrier Formation The role of mammalian target of rapamycin (mTOR) signaling in skin morphogenesis and epidermal development is unknown. Scientists identified mTOR as an essential regulator in skin morphogenesis by epidermis-specific deletion of Mtor in mice. [Nat Commun] Full Article Researchers in vitro cultured human mesenchymal stem cell (hMSC) cell sheets and pre-vascularized hMSC cell sheets were implanted in a rat full thickness skin wound model covered with an autologous split thickness skin graft. [Theranostics] Abstract | Press Release The Impact of Environmental and Endogenous Damage on Somatic Mutation Load in Human Skin Fibroblasts Investigators report the accurate measurement of genome-wide magnitude and spectra of mutations accrued in skin fibroblasts of healthy adult humans. [PLoS Genet] Full Article SKIN CANCERS & DISORDERSThe authors assessed the polo-like kinase 1 expression profile in benign nevi, malignant (stages I–IV) and metastatic melanomas. [Cancer Lett] Abstract The anti-neoplastic nature of epigallocatechin-3-Gallate (EGCG) has been widely shown in cell culture, animal models and clinical studies, its effects on diseases such as lung cancer, colorectal cancer, prostate cancer, stomach cancer, and liver cancer are known, but fewer studies have investigated the effects of EGCG on melanoma cells. Scientists found that TNF Receptor-Associated Factor 6 (TRAF6) is a novel target of EGCG. [Oncotarget] Full Article Scientists evaluated the potential beneficial effects of a new hydrogen sulfide-releasing derivative of naproxen, 2-(6-methoxynapthalen-2-yl)-propionic acid 4-thiocarbamoyl phenyl ester (ATB-346) which inhibits cyclooxygenase-2 activity but also releases H2S. They used cell culture and a mouse melanoma model to evaluate the effect of ATB-346 in vitro growth of human melanoma cells and in vivo melanoma development in mice. [Pharmacol Res] Abstract Researchers investigated the mechanism of type XVII collagen macropinocytosis using DJM-1 cells, a cutaneous squamous cell carcinoma cell line. [Lab Invest] Abstract Targeting CPT1A Enhances Metabolic Therapy in Human Melanoma Cells with the BRAF V600E Mutation. Recent evidence of metabolic alterations has indicated that the fatty acid oxidation (FAO) pathway is used as a carbon source for anabolic processes in some tumors, thus making this pathway a potential target for therapy. Because carnitine palmitoyl transferase 1a (CPT1a) is the rate-limiting enzyme for FAO, the authors evaluated the effects of CPT1A knock-down in BRAF V600E melanoma cell lines. [Int J Biochem Cell Biol] Abstract |
|
|
|
|
REVIEWSResearchers explore the evolution of the epidermal graft harvesting system over the last five decades, the structural advantages of epidermal graft for wound healing and the current hypotheses on the mechanism of wound healing by epidermal graft. [Int Wound J] Abstract Visit our reviews page to see a complete list of reviews in the dermal cell research field. |
|
|
|
|
INDUSTRY NEWSBristol-Myers Squibb’s Yervoy Awarded Prix Galien USA Discovery of the Decade Bristol-Myers Squibb Company announced that it received the Prix Galien USA Discovery of the Decade biotech award for Yervoy, the company’s recombinant, human monoclonal antibody. [Bristol-Myers Squibb Company] Press Release The National Institutes of Health has awarded two co-investigators at Albert Einstein College of Medicine a five-year, $2.6 million grant to make immunotherapy agents that more precisely and effectively treat a variety of cancers while causing far fewer side effects than current immunotherapies. [Albert Einstein College of Medicine] Press Release | |
|
|
|
POLICY NEWSScientific Challenges Loom for Canada’s Popular Prime Minister Many in Canada’s science community say they are reserving judgement, waiting to see whether Trudeau can sustain his string of victories as he tackles some of country’s thorniest science-policy issues. [Nature News] Editorial
|
|
EVENTSNEW European Society for Medical Oncology Asia 2016 Congress Visit our events page to see a complete list of events in the community.
|
|
JOB OPPORTUNITIESNEW Postdoctoral Associate – Pathology (Stony Brook University) Postdoctoral Position – 3D Bioprinting (Inserm) Postdoctoral Position – Immunobiology of Stromal Cells (Institut Pasteur) Clinical Trials Fellow – Dermatology (Brigham and Women’s Hospital) Scientific Director – Global Medical Affairs (Celgene Corporation) Postdoctoral Researcher – Transplantation Immunology (Nuffield Department of Surgical Sciences) Pluripotent Stem Cell Faculty (Stanford University) Postdoctoral Fellowship – Non-Melanoma Skin Cancer (Brigham and Women’s Hospital) Postdoctoral Researcher – Skin Immunology (University Hospital Lausanne) Postdoctoral Scholar – Cancer Biology (The Pennsylvania State University College of Medicine)
Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
|
|
|
Have we missed an important article or publication in Dermal Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. |
|
|
Home Dermal Cell News Volume 2.38 | Oct 31 2016

Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News


